![](/images/general/no_picture/200_user.png)
Michael Gunyoung Lee
Supervisory Patent Examiner (ID: 18346, Phone: (571)272-2398 , Office: P/2876 )
Most Active Art Unit | 2876 |
Art Unit(s) | 2876, 2514 |
Total Applications | 511 |
Issued Applications | 384 |
Pending Applications | 47 |
Abandoned Applications | 80 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16839814
[patent_doc_number] => 20210147826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => METHOD FOR LARGE-SCALE PREPARATION OF PURIFIED PREPARATION OF RECOMBINANT LENTIVIRAL VECTOR AT GMP GRADE
[patent_app_type] => utility
[patent_app_number] => 17/034168
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 153
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034168
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034168 | METHOD FOR LARGE-SCALE PREPARATION OF PURIFIED PREPARATION OF RECOMBINANT LENTIVIRAL VECTOR AT GMP GRADE | Sep 27, 2020 | Pending |
Array
(
[id] => 17981253
[patent_doc_number] => 20220347289
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => NUCLEOTIDE SEQUENCES ENCODING PEPTIDE ANTIGENS OF SARS-COV-2 VIRUS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/260160
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/260160 | NUCLEOTIDE SEQUENCES ENCODING PEPTIDE ANTIGENS OF SARS-COV-2 VIRUS AND USE THEREOF | Aug 18, 2020 | Abandoned |
Array
(
[id] => 17441899
[patent_doc_number] => 20220062404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/418357
[patent_app_country] => US
[patent_app_date] => 2020-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13811
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418357
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/418357 | GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTION | Jan 6, 2020 | Pending |
Array
(
[id] => 17593602
[patent_doc_number] => 20220143175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => NOROVIRUS VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/418197
[patent_app_country] => US
[patent_app_date] => 2019-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18277
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/418197 | NOROVIRUS VACCINES | Dec 29, 2019 | Pending |
Array
(
[id] => 17441906
[patent_doc_number] => 20220062411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => RECOMBINANT VIRUSES AND THE USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/417455
[patent_app_country] => US
[patent_app_date] => 2019-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417455
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/417455 | RECOMBINANT VIRUSES AND THE USES THEREOF | Dec 25, 2019 | Pending |
Array
(
[id] => 17412791
[patent_doc_number] => 20220047695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => COMPOSITIONS COMPRISING SELF-ASSEMBLING VACCINES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/417096
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/417096 | COMPOSITIONS COMPRISING SELF-ASSEMBLING VACCINES AND METHODS OF USING THE SAME | Dec 22, 2019 | Pending |
Array
(
[id] => 17398197
[patent_doc_number] => 20220040287
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENES
[patent_app_type] => utility
[patent_app_number] => 17/414267
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17414267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/414267 | RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENES | Dec 19, 2019 | Pending |
Array
(
[id] => 17426913
[patent_doc_number] => 20220054621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => NOROVIRUS VACCINE FORMULATIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/416810
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416810
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | Dec 19, 2019 | Pending |
Array
(
[id] => 17595832
[patent_doc_number] => 20220145406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER
[patent_app_type] => utility
[patent_app_number] => 17/416988
[patent_app_country] => US
[patent_app_date] => 2019-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416988
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/416988 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | Dec 18, 2019 | Pending |
Array
(
[id] => 17334673
[patent_doc_number] => 20220001004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses
[patent_app_type] => utility
[patent_app_number] => 17/296829
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/296829 | T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses | Nov 25, 2019 | Pending |
Array
(
[id] => 17357124
[patent_doc_number] => 20220017920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => MULTICISTRONIC VECTOR FOR SURFACE ENGINEERING LENTIVIRAL PARTICLES
[patent_app_type] => utility
[patent_app_number] => 17/295599
[patent_app_country] => US
[patent_app_date] => 2019-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11513
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295599
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/295599 | MULTICISTRONIC VECTOR FOR SURFACE ENGINEERING LENTIVIRAL PARTICLES | Nov 20, 2019 | Pending |
Array
(
[id] => 17343954
[patent_doc_number] => 20220010285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => CELLS FOR THE PRODUCTION OF VIRUSES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/295761
[patent_app_country] => US
[patent_app_date] => 2019-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295761
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/295761 | CELLS FOR THE PRODUCTION OF VIRUSES AND METHODS OF USING THE SAME | Nov 19, 2019 | Pending |
Array
(
[id] => 17369969
[patent_doc_number] => 20220025021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
[patent_app_type] => utility
[patent_app_number] => 17/295798
[patent_app_country] => US
[patent_app_date] => 2019-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -179
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/295798 | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Nov 18, 2019 | Pending |
Array
(
[id] => 17336348
[patent_doc_number] => 20220002679
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => Viral Inactivation Methods for Continuous Manufacturing of Antibodies
[patent_app_type] => utility
[patent_app_number] => 17/292652
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292652
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/292652 | Viral Inactivation Methods for Continuous Manufacturing of Antibodies | Nov 13, 2019 | Pending |
Array
(
[id] => 17290968
[patent_doc_number] => 20210386807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => ONCOLYTIC VIRUS FOR CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/288227
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288227
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/288227 | ONCOLYTIC VIRUS FOR CANCER THERAPY | Oct 29, 2019 | Pending |
Array
(
[id] => 17748198
[patent_doc_number] => 20220226401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/274016
[patent_app_country] => US
[patent_app_date] => 2019-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 141333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274016
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/274016 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | Sep 4, 2019 | Pending |
Array
(
[id] => 17170380
[patent_doc_number] => 20210324050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => HUMAN MONOCLONAL ANTIBODIES THAT NEUTRALIZE PANDEMIC GII.4 NOROVIRUSES
[patent_app_type] => utility
[patent_app_number] => 17/271843
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43261
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -92
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271843
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/271843 | HUMAN MONOCLONAL ANTIBODIES THAT NEUTRALIZE PANDEMIC GII.4 NOROVIRUSES | Aug 26, 2019 | Pending |
Array
(
[id] => 17111799
[patent_doc_number] => 20210292396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => ENGINERRED ANTIBODIES TO HIV ENV
[patent_app_type] => utility
[patent_app_number] => 17/263490
[patent_app_country] => US
[patent_app_date] => 2019-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94792
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263490
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/263490 | ENGINERRED ANTIBODIES TO HIV ENV | Jul 25, 2019 | Pending |
Array
(
[id] => 19011736
[patent_doc_number] => 11918637
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Vaccination against porcine circoviruses
[patent_app_type] => utility
[patent_app_number] => 16/973731
[patent_app_country] => US
[patent_app_date] => 2019-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 4494
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16973731
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/973731 | Vaccination against porcine circoviruses | Jun 9, 2019 | Issued |
Array
(
[id] => 16930880
[patent_doc_number] => 20210196769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => Bacteriophage Compositions and Kits and Related Methods
[patent_app_type] => utility
[patent_app_number] => 17/058020
[patent_app_country] => US
[patent_app_date] => 2019-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19239
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/058020 | Bacteriophage compositions and kits and related methods | May 22, 2019 | Issued |